Genomma Lab Internacional. de 과거 수익 실적
과거 기준 확인 5/6
Genomma Lab Internacional. de은 연평균 6.2%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 6.2%였습니다. 매출은 연평균 6.7%의 비율로 증가했습니다. Genomma Lab Internacional. de의 자기자본이익률은 14.4%이고 순이익률은 9.2%입니다.
주요 정보
6.2%
수익 성장률
7.9%
EPS 성장률
| Pharmaceuticals 산업 성장 | 12.4% |
| 매출 성장률 | 6.7% |
| 자기자본 수익률 | 14.4% |
| 순이익 | 9.2% |
| 최근 수익 업데이트 | 30 Sep 2024 |
최근 과거 실적 업데이트
Recent updates
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17
Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Sep 11With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For
Jul 12These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?
Nov 07Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?
Feb 24Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic
Sep 24Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts
Aug 01Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Mar 22Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?
Feb 15Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly
Nov 24Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock
Sep 08Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price
Jun 10Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?
May 24Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?
May 06Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%
Mar 13Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Feb 19Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?
Feb 02Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?
Jan 15What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?
Dec 28Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain
Dec 10
수익 및 비용 분석
수익 및 비용 분석
Genomma Lab Internacional. de 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
| 날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
|---|---|---|---|---|
| 30 Sep 24 | 17,466 | 1,603 | 7,303 | 0 |
| 30 Jun 24 | 16,767 | 1,313 | 7,070 | 0 |
| 31 Mar 24 | 16,486 | 1,045 | 6,720 | 0 |
| 31 Dec 23 | 16,467 | 1,085 | 6,838 | 0 |
| 30 Sep 23 | 17,074 | 1,392 | 6,988 | 0 |
| 30 Jun 23 | 17,030 | 1,421 | 7,002 | 0 |
| 31 Mar 23 | 16,983 | 1,408 | 6,932 | 0 |
| 31 Dec 22 | 16,820 | 1,389 | 6,922 | 0 |
| 30 Sep 22 | 16,778 | 1,359 | 7,185 | 0 |
| 30 Jun 22 | 16,412 | 1,353 | 7,043 | 0 |
| 31 Mar 22 | 15,954 | 1,328 | 6,877 | 0 |
| 31 Dec 21 | 15,487 | 1,308 | 6,570 | 0 |
| 30 Sep 21 | 14,868 | 1,352 | 6,135 | 0 |
| 30 Jun 21 | 14,312 | 1,368 | 5,872 | 0 |
| 31 Mar 21 | 14,083 | 1,416 | 5,736 | 0 |
| 31 Dec 20 | 13,870 | 1,404 | 5,666 | 0 |
| 30 Sep 20 | 13,619 | 1,179 | 5,899 | 0 |
| 30 Jun 20 | 13,268 | 1,003 | 5,824 | 0 |
| 31 Mar 20 | 12,910 | 886 | 5,810 | 0 |
| 31 Dec 19 | 12,713 | 750 | 5,824 | 0 |
| 30 Sep 19 | 12,617 | 935 | 5,815 | 0 |
| 30 Jun 19 | 12,274 | 925 | 5,735 | 0 |
| 31 Mar 19 | 11,921 | 986 | 5,615 | 0 |
| 31 Dec 18 | 11,794 | 1,109 | 5,578 | 0 |
| 30 Sep 18 | 11,556 | 1,242 | 5,264 | 0 |
| 30 Jun 18 | 11,900 | 1,249 | 5,378 | 0 |
| 31 Mar 18 | 11,886 | 1,218 | 5,454 | 0 |
| 31 Dec 17 | 12,078 | 1,279 | 5,622 | 0 |
| 30 Sep 17 | 11,898 | 958 | 6,295 | 0 |
| 30 Jun 17 | 11,741 | 1,212 | 6,383 | 0 |
| 31 Mar 17 | 11,669 | -1,603 | 7,551 | 0 |
| 31 Dec 16 | 11,316 | -1,681 | 7,491 | 0 |
| 30 Sep 16 | 11,287 | -3,447 | 8,438 | 0 |
| 30 Jun 16 | 10,988 | -3,759 | 8,363 | 0 |
| 31 Mar 16 | 11,125 | -895 | 7,325 | 0 |
| 31 Dec 15 | 11,042 | -1,137 | 7,334 | 0 |
| 30 Sep 15 | 11,211 | 1,109 | 5,791 | 0 |
| 30 Jun 15 | 11,946 | 1,410 | 5,868 | 0 |
| 31 Mar 15 | 11,871 | 1,396 | 5,748 | 0 |
| 31 Dec 14 | 11,541 | 1,432 | 5,569 | 0 |
| 30 Sep 14 | 12,375 | 1,776 | 5,531 | 0 |
| 30 Jun 14 | 12,082 | 1,766 | 5,444 | 0 |
| 31 Mar 14 | 11,715 | 1,775 | 5,228 | 0 |
| 31 Dec 13 | 11,361 | 1,752 | 5,017 | 0 |
양질의 수익: LAB B 은 높은 수익을 보유하고 있습니다.
이익 마진 증가: LAB B 의 현재 순이익 이익률 (9.2%) 작년보다 높습니다 (8.2%).
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: LAB B 의 수입은 지난 5년 동안 매년 6.2% 씩 증가했습니다.
성장 가속화: 지난 1년간 LAB B 의 수익 증가율( 15.1% )은 연간 평균( 6.2% 초과합니다. ).
수익 대 산업: 지난 1년간 LAB B 수익 증가율( 15.1% )은 Pharmaceuticals 업계 8.8% 초과했습니다.
자기자본 수익률
높은 ROE: LAB B 의 자본 수익률( 14.4% )은 낮음으로 간주됩니다.